Consonance Capital Management’s Pacira BioSciences PCRX Stock Holding History

Consonance Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,799,916	Closed	-$122M	–	33
2019 Q2	$122M	Sell	2,799,916 -852,218	-23%	-$36.2M	8.62%	4
2019 Q1	$139M	Hold	3,652,134	–	–	8.77%	3
2018 Q4	$157M	Hold	3,652,134	–	–	11.56%	1
2018 Q3	$180M	Sell	3,652,134 -101,700	-3%	-$4.4M	9.67%	1
2018 Q2	$120M	Buy	3,753,834 +1,118,918	+42%	+$38.6M	7.76%	3
2018 Q1	$82.1M	Buy	2,634,916 +1,032,582	+64%	+$36.8M	7.5%	5
2017 Q4	$73.1M	Buy	1,602,334 +222,200	+16%	+$8.81M	6.61%	8
2017 Q3	$51.8M	Buy	+1,380,134	New	+$55.5M	5.73%	10
2017 Q2	–	Sell	-972,535	Closed	-$44.3M	–	22
2017 Q1	$44.3M	Buy	972,535 +340,730	+54%	+$14.7M	4.65%	11
2016 Q4	$20.4M	Buy	+631,805	New	+$21.1M	2.24%	16

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Consonance Capital Management's PCRX Position: Q3 2019 in Review

Consonance Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 2,799,916 shares — an estimated $122M sold.

Consonance Capital Management first reported a position in PCRX in Q4 2016 and held it in 10 quarters. The position peaked at $180M in Q3 2018. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Consonance Capital Management reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Consonance Capital Management sold 2,799,916 Pacira BioSciences shares in Q3 2019, an estimated $122M.
Consonance Capital Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 10 quarters.
Consonance Capital Management's Pacira BioSciences position peaked at $180M in Q3 2018.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.